ETV3 and ETV6 enable monocyte differentiation into dendritic cells by repressing macrophage fate commitment

Javiera Villar(Inserm), Adeline Cros(Inserm), Alba de Juan(Inserm), Lamine Alaoui(Inserm), Pierre‐Emmanuel Bonté(Inserm), Colleen M. Lau(New York University), Ioanna Tiniakou(New York University), Boris Reizis(New York University), Élodie Segura(Inserm)
Nature Immunology
December 21, 2022
Cited by 57Open Access
Full Text

Abstract

In inflamed tissues, monocytes differentiate into macrophages (mo-Macs) or dendritic cells (mo-DCs). In chronic nonresolving inflammation, mo-DCs are major drivers of pathogenic events. Manipulating monocyte differentiation would therefore be an attractive therapeutic strategy. However, how the balance of mo-DC versus mo-Mac fate commitment is regulated is not clear. In the present study, we show that the transcriptional repressors ETV3 and ETV6 control human monocyte differentiation into mo-DCs. ETV3 and ETV6 inhibit interferon (IFN)-stimulated genes; however, their action on monocyte differentiation is independent of IFN signaling. Instead, we find that ETV3 and ETV6 directly repress mo-Mac development by controlling MAFB expression. Mice deficient for Etv6 in monocytes have spontaneous expression of IFN-stimulated genes, confirming that Etv6 regulates IFN responses in vivo. Furthermore, these mice have impaired mo-DC differentiation during inflammation and reduced pathology in an experimental autoimmune encephalomyelitis model. These findings provide information about the molecular control of monocyte fate decision and identify ETV6 as a therapeutic target to redirect monocyte differentiation in inflammatory disorders.


Related Papers

No related papers found

Powered by citation graph analysis